Large-scale testing (Phase 3)Study completedNCT02104817
What this trial is testing
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Who this might be right for
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
AstraZeneca 13,078